The O
risk O
of O
cancer B
, O
especially O
lymphoid B
neoplasias I
, O
is O
substantially O
elevated O
in O
A B
- I
T I
patients O
and O
has O
long O
been O
associated O
with O
chromosomal O
instability O
. O

By O
analysing O
tumour B
DNA O
from O
patients O
with O
sporadic B
T I
- I
cell I
prolymphocytic I
leukaemia I
( O
T B
- I
PLL I
) O
, O
a O
rare O
clonal B
malignancy I
with O
similarities O
to O
a O
mature B
T I
- I
cell I
leukaemia I
seen O
in O
A B
- I
T I
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B
- I
PLL I
. O

In O
marked O
contrast O
to O
the O
ATM O
mutation O
pattern O
in O
A B
- I
T I
, O
the O
most O
frequent O
nucleotide O
changes O
in O
this O
leukaemia B
were O
missense O
mutations O
. O

In O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p53 O
gene O
, O
suggesting O
that O
this O
tumour B
suppressor O
is O
not O
frequently O
altered O
in O
this O
leukaemia B
. O

In O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p53 O
gene O
, O
suggesting O
that O
this O
tumour B
suppressor O
is O
not O
frequently O
altered O
in O
this O
leukaemia B
. O

Occasional O
missense O
mutations O
in O
ATM O
were O
also O
found O
in O
tumour B
DNA O
from O
patients O
with O
B B
- I
cell I
non I
- I
Hodgkins I
lymphomas I
( O
B B
- I
NHL I
) O
and O
a O
B B
- I
NHL I
cell O
line O
. O

The O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
ATM O
in O
the O
majority O
of O
mutated O
tumours B
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B
T I
- I
PLL I
and O
suggests O
that O
ATM O
acts O
as O
a O
tumour B
suppressor O
. O

The O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
ATM O
in O
the O
majority O
of O
mutated O
tumours B
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B
T I
- I
PLL I
and O
suggests O
that O
ATM O
acts O
as O
a O
tumour B
suppressor O
. O

Myotonic B
dystrophy I
( O
DM B
) O
, O
the O
most O
prevalent O
muscular B
disorder I
in O
adults O
, O
is O
caused O
by O
( O
CTG O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
DM B
protein O
kinase O
; O
DMPK O
) O
and O
involves O
changes O
in O
cytoarchitecture O
and O
ion O
homeostasis O
. O

Myotonic B
dystrophy I
( O
DM B
) O
, O
the O
most O
prevalent O
muscular B
disorder I
in O
adults O
, O
is O
caused O
by O
( O
CTG O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
DM B
protein O
kinase O
; O
DMPK O
) O
and O
involves O
changes O
in O
cytoarchitecture O
and O
ion O
homeostasis O
. O

In O
most O
patients O
with O
isolated O
unilateral B
retinoblastoma I
, O
tumor B
development O
is O
initiated O
by O
somatic O
inactivation O
of O
both O
alleles O
of O
the O
RB1 O
gene O
. O

However O
, O
some O
of O
these O
patients O
can O
transmit O
retinoblastoma B
predisposition O
to O
their O
offspring O
. O

To O
determine O
the O
frequency O
and O
nature O
of O
constitutional O
RB1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B
retinoblastoma I
, O
we O
analyzed O
DNA O
from O
peripheral O
blood O
and O
from O
tumor B
tissue O
. O

The O
analysis O
of O
tumors B
from O
54 O
( O
71 O
% O
) O
of O
76 O
informative O
patients O
showed O
loss O
of O
constitutional O
heterozygosity O
( O
LOH O
) O
at O
intragenic O
loci O
. O

For O
39 O
randomly O
selected O
tumors B
, O
SSCP O
, O
hetero O
- O
duplex O
analysis O
, O
sequencing O
, O
and O
Southern O
blot O
analysis O
were O
used O
to O
identify O
mutations O
. O

Mutations O
were O
detected O
in O
21 O
( O
91 O
% O
) O
of O
23 O
tumors B
with O
LOH O
. O

In O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B
without O
LOH O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B
without O
LOH O
, O
both O
mutations O
were O
found O
. O

In O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B
without O
LOH O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B
without O
LOH O
, O
both O
mutations O
were O
found O
. O

Thus O
, O
a O
total O
of O
45 O
mutations O
were O
identified O
in O
tumors B
of O
36 O
patients O
. O

In O
2 O
patients O
without O
a O
detectable O
mutation O
in O
peripheral O
blood O
, O
mosaicism O
was O
suggested O
because O
1 O
of O
the O
patients O
showed O
multifocal O
tumors B
and O
the O
other O
later O
developed O
bilateral B
retinoblastoma I
. O

In O
conclusion O
, O
our O
results O
emphasize O
that O
the O
manifestation O
and O
transmissibility O
of O
retinoblastoma B
depend O
on O
the O
nature O
of O
the O
first O
mutation O
, O
its O
time O
in O
development O
, O
and O
the O
number O
and O
types O
of O
cells O
that O
are O
affected O
. O
. O

Normal O
hemolytic O
titers O
were O
restored O
to O
both O
homozygous O
C5 B
- I
deficient I
( O
C5D B
) O
sera O
by O
addition O
of O
highly O
purified O
human O
C5 O
. O

In O
specific O
C5 O
titrations O
, O
however O
, O
it O
was O
noted O
that O
when O
limited O
amounts O
of O
C5 O
were O
assayed O
in O
the O
presence O
of O
low O
dilutions O
of O
either O
C5D B
serum O
, O
curving O
rather O
than O
linear O
dose O
- O
response O
plots O
were O
consistently O
obtained O
, O
suggesting O
some O
inhibitory O
effect O
. O

Further O
studies O
suggested O
that O
low O
dilutions O
of O
C5D B
serum O
contain O
a O
factor O
( O
or O
factors O
) O
interfering O
at O
some O
step O
in O
the O
hemolytic O
assay O
of O
C5 O
, O
rather O
than O
a O
true O
C5 O
inhibitor O
or O
inactivator O
. O

Of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B
, O
vasculitis B
, O
and O
arthritis B
in O
an O
individual O
lacking O
C5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B
infections I
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

Of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B
, O
vasculitis B
, O
and O
arthritis B
in O
an O
individual O
lacking O
C5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B
infections I
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

Of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B
, O
vasculitis B
, O
and O
arthritis B
in O
an O
individual O
lacking O
C5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B
infections I
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

Other O
observations O
indicate O
that O
the O
C5D B
state O
is O
compatible O
with O
normal O
coagulation O
function O
and O
the O
capacity O
to O
mount O
a O
neutrophilic O
leukocytosis O
during O
pyogenic B
infection I
. O
. O

OBJECTIVE O
To O
determine O
the O
relative O
effects O
of O
genetic O
and O
environmental O
factors O
in O
susceptibility O
to O
ankylosing B
spondylitis I
( O
AS B
) O
. O

METHODS O
Twins O
with O
AS B
were O
identified O
from O
the O
Royal O
National O
Hospital O
for O
Rheumatic B
Diseases I
database O
. O

Genetic O
and O
environmental O
variance O
components O
were O
assessed O
with O
the O
program O
Mx O
, O
using O
data O
from O
this O
and O
previous O
studies O
of O
twins O
with O
AS B
. O

CONCLUSION O
Susceptibility O
to O
AS B
is O
largely O
genetically O
determined O
, O
and O
the O
environmental O
trigger O
for O
the O
disease O
is O
probably O
ubiquitous O
. O

HLA O
- O
B27 O
accounts O
for O
a O
minority O
of O
the O
overall O
genetic O
susceptibility O
to O
AS B
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
predispose O
women O
to O
early O
- O
onset O
breast B
and I
ovarian I
cancer I
by O
compromising O
the O
genes O
presumptive O
function O
as O
a O
tumor B
suppressor O
. O

This O
cell O
cycle O
- O
dependent O
colocalization O
of O
BARD1 O
and O
BRCA1 O
indicates O
a O
role O
for O
BARD1 O
in O
BRCA1 O
- O
mediated O
tumor B
suppression O
. O

Recent O
studies O
have O
shown O
that O
hereditary B
hemochromatosis I
( O
HH B
) O
is O
likely O
to O
be O
caused O
by O
homozygosity O
for O
a O
Cys282Tyr O
mutation O
in O
the O
HFE O
gene O
located O
4 O
. O

Comparisons O
with O
allele O
frequencies O
based O
on O
prevalence O
estimates O
of O
HH B
showed O
some O
disagreements O
with O
the O
RFLP O
data O
, O
particularly O
in O
Finns O
. O

The O
newly O
described O
HFE O
marker O
provides O
a O
new O
approach O
to O
the O
screening O
of O
HH B
as O
well O
as O
studies O
of O
the O
relationship O
between O
the O
HFE O
Tyr O
allele O
and O
different O
disorders O
including O
cancer B

Autosomal B
dominant I
neurohypophyseal I
diabetes I
insipidus I
( O
ADNDI B
) O
is O
an O
inherited B
disease I
caused O
by O
progressive O
degeneration O
of O
the O
magnocellular O
neurons O
of O
the O
hypothalamus O
leading O
to O
decreased O
ability O
to O
produce O
the O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
. O

The O
genetic O
locus O
of O
the O
disease O
is O
the O
AVP O
- O
neurophysin O
II O
( O
NPII O
) O
gene O
, O
and O
mutations O
that O
cause O
ADNDI B
have O
been O
found O
in O
both O
the O
signal O
peptide O
of O
the O
prepro O
- O
AVP O
- O
NPII O
precursor O
and O
within O
NPII O
itself O
. O

Sporadic B
prostate I
carcinoma I
is O
the O
most O
common O
male B
cancer I
in O
the O
Western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B
remain O
to O
be O
elucidated O
. O

A O
new O
tumor B
suppressor O
gene O
, O
PTEN O
/ O
MMAC1 O
, O
was O
isolated O
recently O
at O
this O
region O
of O
chromosome O
10q23 O
and O
found O
to O
be O
inactivated O
by O
mutation O
in O
three O
prostate B
cancer I
cell O
lines O
. O

The O
identification O
of O
the O
second O
mutational O
event O
in O
10 O
( O
43 O
% O
) O
tumors B
establishes O
PTEN O
/ O
MMAC1 O
as O
a O
main O
inactivation O
target O
of O
10q O
loss O
in O
sporadic B
prostate I
cancer I
. O
. O

The O
first O
predictive O
testing O
for O
Huntington B
disease I
( O
HD B
) O
was O
based O
on O
analysis O
of O
linked O
polymorphic O
DNA O
markers O
to O
estimate O
the O
likelihood O
of O
inheriting O
the O
mutation O
for O
HD B
. O

The O
first O
predictive O
testing O
for O
Huntington B
disease I
( O
HD B
) O
was O
based O
on O
analysis O
of O
linked O
polymorphic O
DNA O
markers O
to O
estimate O
the O
likelihood O
of O
inheriting O
the O
mutation O
for O
HD B
. O

With O
direct O
tests O
for O
the O
HD B
mutation O
, O
we O
have O
assessed O
the O
accuracy O
of O
results O
obtained O
by O
linkage O
approaches O
when O
requested O
to O
do O
so O
by O
the O
test O
individuals O
. O

We O
report O
a O
rare O
case O
of O
paternally O
transmitted O
congenital B
myotonic I
dystrophy I
( O
DM B
) O
. O

His O
two O
sibs O
suffer O
from O
childhood O
onset O
DM B
. O

Their O
late O
father O
had O
the O
adult O
type O
of O
DM B
, O
with O
onset O
around O
30 O
years O
. O

Decreased O
fertility O
of O
males O
with O
adult O
onset O
DM B
and O
contraction O
of O
the O
repeat O
upon O
male O
transmission O
contribute O
to O
the O
almost O
absent O
occurrence O
of O
paternal O
transmission O
of O
congenital B
DM I
. O

We O
conclude O
that O
paternal O
transmission O
of O
congenital B
DM I
is O
rare O
and O
preferentially O
occurs O
with O
onset O
of O
DM B
past O
30 O
years O
in O
the O
father O
. O
. O

The O
mutation O
is O
in O
an O
area O
of O
the O
gene O
that O
encodes O
the O
protein O
- O
binding O
region O
known O
as O
the O
pocket O
region O
and O
has O
been O
detected O
in O
other O
cases O
of O
retinoblastoma B
. O
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B
of I
hex I
A I
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B
of I
hex I
A I
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
. O

Previous O
family O
studies O
suggested O
that O
these O
individuals O
may O
be O
compound O
heterozygotes O
for O
the O
common O
mutant O
TSD B
gene O
and O
a O
rare O
( O
allelic O
) O
mutant O
gene O
. O

Heterozygotes O
for O
the O
rare O
mutant O
may O
be O
indistinguishable O
from O
heterozygotes O
for O
the O
common O
TSD B
mutant O
. O

However O
, O
direct O
visualization O
and O
quantitation O
of O
hex O
A O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
prenatal O
diagnosis O
of O
TSD B
in O
fetuses O
having O
the O
incomplete O
hex B
A I
deficiency I
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O

The O
tumor B
suppressor O
gene O
Smad4 O
/ O
Dpc4 O
is O
required O
for O
gastrulation O
and O
later O
for O
anterior O
development O
of O
the O
mouse O
embryo O
. O

Mutations O
in O
the O
SMAD4 O
/ O
DPC4 O
tumor B
suppressor O
gene O
, O
a O
key O
signal O
transducer O
in O
most O
TGFbeta O
- O
related O
pathways O
, O
are O
involved O
in O
50 O
% O
of O
pancreatic B
cancers I
. O

Prevalence O
of O
p16 O
and O
CDK4 O
germline O
mutations O
in O
48 O
melanoma B
- O
prone O
families O
in O
France O
. O

Germline O
mutations O
in O
the O
p16 O
and O
CDK4 O
genes O
have O
been O
reported O
in O
a O
subset O
of O
melanoma B
pedigrees O
, O
but O
their O
prevalence O
is O
not O
well O
known O
. O

We O
searched O
for O
such O
germline O
mutations O
in O
48 O
French O
melanoma B
- O
prone O
families O
selected O
according O
to O
two O
major O
criteria O
families O
with O
at O
least O
three O
affected O
members O
( O
n O
= O
20 O
) O
or O
families O
with O
two O
affected O
members O
, O
one O
of O
them O
affected O
before O
the O
age O
of O
50 O
( O
n O
= O
28 O
) O
, O
and O
one O
additional O
minor O
criterion O
. O

In O
summary O
, O
our O
results O
show O
frequent O
involvement O
of O
the O
p16 O
gene O
in O
familial B
melanoma I
and O
confirm O
the O
role O
of O
the O
CDK4 O
gene O
as O
a O
melanoma B
- O
predisposing O
gene O
. O
. O

The O
genetic O
basis O
of O
myotonic B
dystrophy I
( O
DM B
) O
is O
the O
expansion O
of O
an O
unstable O
CTG O
repeat O
in O
the O
34 O
UTR O
of O
the O
DM B
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

The O
genetic O
basis O
of O
myotonic B
dystrophy I
( O
DM B
) O
is O
the O
expansion O
of O
an O
unstable O
CTG O
repeat O
in O
the O
34 O
UTR O
of O
the O
DM B
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

One O
of O
the O
principal O
features O
of O
the O
DM B
mutation O
is O
an O
extraordinarily O
high O
level O
of O
somatic O
mosaicism O
, O
due O
to O
an O
extremely O
high O
degree O
of O
somatic O
instability O
both O
within O
and O
between O
different O
tissues O
. O

In O
order O
to O
further O
characterize O
the O
dynamics O
of O
DM B
CTG O
repeat O
somatic O
instability O
, O
we O
have O
studied O
repeat O
length O
changes O
over O
time O
in O
111 O
myotonic B
dystrophy I
patients O
with O
varying O
clinical O
severity O
and O
CTG O
repeat O
size O
over O
time O
intervals O
of O
1 O
- O
7 O
years O
. O

Aspartylglucosaminuria B
among O
Palestinian O
Arabs O
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
a O
rare O
disorder B
of I
glycoprotein I
metabolism I
caused O
by O
the O
deficiency B
of I
the I
lysosomal I
enzyme I
aspartylglucosaminidase I
( O
AGA O
) O
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
a O
rare O
disorder B
of I
glycoprotein I
metabolism I
caused O
by O
the O
deficiency B
of I
the I
lysosomal I
enzyme I
aspartylglucosaminidase I
( O
AGA O
) O
. O

AGU B
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
and O
occurs O
with O
a O
high O
frequency O
in O
Finland O
because O
of O
a O
founder O
effect O
. O

While O
very O
few O
patients O
with O
AGU B
have O
been O
reported O
from O
non O
- O
Finnish O
origin O
, O
we O
diagnosed O
the O
disorder O
in O
8 O
patients O
originating O
from O
3 O
unrelated O
families O
, O
all O
Palestinian O
Arabs O
from O
the O
region O
of O
Jerusalem O
. O

The O
clinical O
diagnosis O
of O
AGU B
is O
often O
difficult O
, O
in O
particular O
early O
in O
the O
course O
of O
the O
disease O
, O
and O
most O
of O
the O
patients O
are O
diagnosed O
after O
the O
age O
of O
5 O
years O
. O

In O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B
recessive I
syndrome I
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B
. O

Heterozygotes O
for O
the O
ATM O
gene O
have O
no O
clinical O
expression O
of O
A B
- I
T I
but O
may O
be O
cancer B
prone O
with O
a O
moderate O
increase O
in O
in O
vitro O
radiosensitivity O
. O

In O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
familial B
and I
sporadic I
cancers I
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
ATM O
mutations O
in O
tumor B
risk O
or O
development O
. O
. O

The O
inactivation O
of O
the O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
tumor I
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B
cancer I
syndrome I
and O
is O
associated O
with O
sporadic B
renal I
cell I
carcinomas I
( O
RCC B
) O
and O
brain B
hemangioblastomas I
. O

VHL O
- O
negative O
786 O
- O
0 O
RCC B
cells O
are O
tumorigenic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
reintroduction O
of O
VHL B
. O

VHL O
- O
negative O
786 O
- O
0 O
RCC B
cells O
are O
tumorigenic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
reintroduction O
of O
VHL B
. O

The O
786 O
- O
0 O
cell O
line O
, O
like O
many O
cancer B
cells O
, O
fails O
to O
exit O
the O
cell O
cycle O
upon O
serum O
withdrawal O
. O

Here O
, O
it O
is O
shown O
that O
reintroduction O
of O
the O
wild O
- O
type O
VHL B
gene O
restores O
the O
ability O
of O
VHL O
- O
negative O
RCC B
cancer I
cells O
to O
exit O
the O
cell O
cycle O
and O
enter O
G0 O
/ O
quiescence O
in O
low O
serum O
. O

Both O
VHL O
- O
positive O
and O
VHL O
- O
negative O
RCC B
cells O
exit O
the O
cell O
cycle O
by O
contact O
inhibition O
. O

The O
cyclin O
- O
dependent O
kinase O
inhibitor O
, O
p27 O
, O
accumulates O
upon O
serum O
withdrawal O
, O
only O
in O
the O
presence O
of O
VHL B
, O
as O
a O
result O
of O
the O
stabilization O
of O
the O
protein O
. O

We O
propose O
that O
the O
loss O
of O
wild O
- O
type O
VHL B
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B
formation O
. O

We O
propose O
that O
the O
loss O
of O
wild O
- O
type O
VHL B
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B
formation O
. O

This O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
VHL B
, O
implicating O
VHL B
as O
the O
first O
tumor B
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

This O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
VHL B
, O
implicating O
VHL B
as O
the O
first O
tumor B
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

This O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
VHL B
, O
implicating O
VHL B
as O
the O
first O
tumor B
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

Piebaldism B
with O
deafness B
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

Piebaldism B
with O
deafness B
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

In O
a O
South O
African O
girl O
of O
Xhosa O
stock O
with O
severe O
piebaldism B
and O
profound O
congenital O
sensorineural B
deafness I
we O
identified O
a O
novel O
missense O
substitution O
at O
a O
highly O
conserved O
residue O
in O
the O
intracellular O
kinase O
domain O
of O
the O
KIT O
proto O
- O
oncogene O
, O
R796G O
. O

Though O
auditory B
anomalies I
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spotting O
( O
W O
) O
due O
to O
KIT O
mutations O
, O
deafness B
is O
not O
typical O
in O
human O
piebaldism B
. O

Though O
auditory B
anomalies I
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spotting O
( O
W O
) O
due O
to O
KIT O
mutations O
, O
deafness B
is O
not O
typical O
in O
human O
piebaldism B
. O

Thus O
, O
the O
occurrence O
of O
sensorineural B
deafness I
in O
this O
patient O
extends O
considerably O
the O
phenotypic O
range O
of O
piebaldism B
due O
to O
KIT O
gene O
mutation O
in O
humans O
and O
tightens O
the O
clinical O
similarity O
between O
piebaldism B
and O
the O
various O
forms O
of O
Waardenburg B
syndrome I
. O
. O

Thus O
, O
the O
occurrence O
of O
sensorineural B
deafness I
in O
this O
patient O
extends O
considerably O
the O
phenotypic O
range O
of O
piebaldism B
due O
to O
KIT O
gene O
mutation O
in O
humans O
and O
tightens O
the O
clinical O
similarity O
between O
piebaldism B
and O
the O
various O
forms O
of O
Waardenburg B
syndrome I
. O
. O

Patients O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
, O
a O
usually O
nonlethal O
form O
of O
junctional B
epidermolysis I
bullosa I
, O
have O
generalized O
blistering B
, O
nail B
dystrophy I
, O
patchy B
alopecia I
, O
and O
dental B
abnormalities I
. O

The O
haptoglobin O
- O
gene O
deletion O
responsible O
for O
anhaptoglobinemia B
. O

We O
have O
found O
an O
allelic O
deletion O
of O
the O
haptoglobin O
( O
Hp O
) O
gene O
from O
an O
individual O
with O
anhaptoglobinemia B
. O

Southern O
blot O
and O
PCR O
analyses O
have O
indicated O
that O
the O
individual O
with O
anhaptoglobinemia B
was O
homozygous O
for O
the O
gene O
deletion O
and O
that O
the O
gene O
deletion O
was O
included O
at O
least O
from O
the O
promoter O
region O
of O
Hp O
to O
Hpr O
alpha O
but O
not O
to O
Hpr O
beta O
( O
Hpdel O
) O
. O

In O
addition O
, O
we O
found O
seven O
individuals O
with O
hypohaptoglobinemia B
in O
three O
families O
, O
and O
the O
genotypes O
of O
six O
of O
the O
seven O
individuals O
were O
found O
to O
be O
Hp2 O
/ O
Hpdel O
. O

The O
phenotypes O
and O
genotypes O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
hypohaptoglobinemic B
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
the O
mother O
to O
be O
Hp2 O
- O
1 O
and O
Hp1 O
/ O
Hp2 O
, O
one O
of O
the O
two O
children O
to O
be O
hypohaptoglobinemic B
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
and O
the O
other O
child O
to O
be O
Hp1 O
and O
Hp1 O
/ O
Hpdel O
, O
showing O
an O
anomalous O
inheritance O
of O
Hp O
phenotypes O
in O
the O
child O

The O
phenotypes O
and O
genotypes O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
hypohaptoglobinemic B
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
the O
mother O
to O
be O
Hp2 O
- O
1 O
and O
Hp1 O
/ O
Hp2 O
, O
one O
of O
the O
two O
children O
to O
be O
hypohaptoglobinemic B
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
and O
the O
other O
child O
to O
be O
Hp1 O
and O
Hp1 O
/ O
Hpdel O
, O
showing O
an O
anomalous O
inheritance O
of O
Hp O
phenotypes O
in O
the O
child O

On O
the O
basis O
of O
the O
present O
study O
, O
the O
mechanism O
of O
anhaptoglobinemia B
and O
the O
mechanism O
of O
anomalous O
inheritance O
of O
Hp O
phenotypes O
were O
well O
explained O
. O

However O
, O
the O
mechanism O
of O
hypohaptoglobinemia B
remains O
unknown O

ATM O
mutations O
and O
phenotypes O
in O
ataxia B
- I
telangiectasia I
families O
in O
the O
British O
Isles O
: O
expression O
of O
mutant O
ATM O
and O
the O
risk O
of O
leukemia B
, O
lymphoma B
, O
and O
breast B
cancer I
. O

ATM O
mutations O
and O
phenotypes O
in O
ataxia B
- I
telangiectasia I
families O
in O
the O
British O
Isles O
: O
expression O
of O
mutant O
ATM O
and O
the O
risk O
of O
leukemia B
, O
lymphoma B
, O
and O
breast B
cancer I
. O

In O
addition O
, O
we O
have O
studied O
18 O
A B
- I
T I
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B
, O
lymphoma B
, O
preleukemic O
T O
- O
cell O
proliferation O
, O
or O
Hodgkin B
lymphoma I
, O
mostly O
in O
childhood O
. O

In O
addition O
, O
we O
have O
studied O
18 O
A B
- I
T I
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B
, O
lymphoma B
, O
preleukemic O
T O
- O
cell O
proliferation O
, O
or O
Hodgkin B
lymphoma I
, O
mostly O
in O
childhood O
. O

The O
hemochromatosis B
gene O
product O
complexes O
with O
the O
transferrin O
receptor O
and O
lowers O
its O
affinity O
for O
ligand O
binding O
. O

The O
tumour B
suppressor O
gene O
PTEN O
, O
which O
maps O
to O
10q23 O
. O

3 O
and O
encodes O
a O
403 O
amino O
acid O
dual O
specificity O
phosphatase O
( O
protein O
tyrosine O
phosphatase O
; O
PTPase O
) O
, O
was O
shown O
recently O
to O
play O
a O
broad O
role O
in O
human O
malignancy B
. O

Somatic O
PTEN O
deletions O
and O
mutations O
were O
observed O
in O
sporadic B
breast I
, I
brain I
, I
prostate I
and I
kidney I
cancer I
cell O
lines O
and O
in O
several O
primary O
tumours B
such O
as O
endometrial B
carcinomas I
, O
malignant B
melanoma I
and O
thyroid B
tumours I
. O

In O
addition O
, O
PTEN O
was O
identified O
as O
the O
susceptibility O
gene O
for O
two O
hamartoma B
syndromes I
Cowden B
disease I
( O
CD B
; O
MIM O
158350 O
) O
and O
Bannayan B
- I
Zonana I
( I
BZS I
) I
or I
Ruvalcaba I
- I
Riley I
- I
Smith I
syndrome I
( O
MIM O
153480 O
) O
. O

Constitutive O
DNA O
from O
37 O
CD B
families O
and O
seven O
BZS B
families O
was O
screened O
for O
germline O
PTEN O
mutations O
. O

Constitutive O
DNA O
from O
37 O
CD B
families O
and O
seven O
BZS B
families O
was O
screened O
for O
germline O
PTEN O
mutations O
. O

PTEN O
mutations O
were O
identified O
in O
30 O
of O
37 O
( O
81 O
% O
) O
CD B
families O
, O
including O
missense O
and O
nonsense O
point O
mutations O
, O
deletions O
, O
insertions O
, O
a O
deletion O
/ O
insertion O
and O
splice O
site O
mutations O
. O

A O
hot O
spot O
for O
PTEN O
mutation O
in O
CD B
was O
identified O
in O
exon O
5 O
that O
contains O
the O
PTPase O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
CD B
mutations O
identified O
in O
this O
exon O
. O

A O
hot O
spot O
for O
PTEN O
mutation O
in O
CD B
was O
identified O
in O
exon O
5 O
that O
contains O
the O
PTPase O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
CD B
mutations O
identified O
in O
this O
exon O
. O

Germline O
PTEN O
mutations O
were O
identified O
in O
four O
of O
seven O
( O
57 O
% O
) O
BZS B
families O
studied O
. O

It O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
R233X O
, O
was O
observed O
in O
the O
germline O
DNA O
from O
two O
unrelated O
CD B
families O
and O
one O
BZS B
family O
. O

It O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
R233X O
, O
was O
observed O
in O
the O
germline O
DNA O
from O
two O
unrelated O
CD B
families O
and O
one O
BZS B
family O
. O

Genotype O
- O
phenotype O
studies O
were O
not O
performed O
on O
this O
small O
group O
of O
BZS B
families O
. O

However O
, O
genotype O
- O
phenotype O
analysis O
inthe O
group O
of O
CD B
families O
revealed O
two O
possible O
associations O
worthy O
of O
follow O
- O
up O
in O
independent O
analyses O
. O

The O
first O
was O
an O
association O
noted O
in O
the O
group O
of O
CD B
families O
with O
breast B
disease I
. O

However O
, O
these O
observations O
would O
need O
to O
be O
confirmed O
by O
studying O
a O
larger O
number O
of O
CD B
families O
. O

Complement B
component I
C6 I
deficiency I
( O
C6D B
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
African O
- O
American O
male O
with O
meningococcal B
meningitis I
. O

The O
patients O
father O
and O
two O
brothers O
also O
had O
C6D B
, O
but O
gave O
no O
history O
of O
meningitis B
or O
other O
neisserial B
infection I
. O

The O
patients O
father O
and O
two O
brothers O
also O
had O
C6D B
, O
but O
gave O
no O
history O
of O
meningitis B
or O
other O
neisserial B
infection I
. O

The O
first O
, O
1195delC O
located O
in O
exon O
7 O
, O
is O
a O
novel O
mutation O
, O
while O
the O
second O
, O
1936delG O
in O
exon O
12 O
, O
has O
been O
described O
before O
to O
cause O
C6D B
in O
an O
unrelated O
African O
- O
American O
individual O
. O

Mutations O
in O
PAX6 O
are O
responsible O
for O
human O
aniridia B
and O
have O
also O
been O
found O
in O
patients O
with O
Peters B
anomaly I
, O
with O
congenital B
cataracts I
, O
with O
autosomal B
dominant I
keratitis I
, O
and O
with O
isolated B
foveal I
hypoplasia I
. O

No O
locus O
other O
than O
chromosome O
11p13 O
has O
been O
implicated O
in O
aniridia B
, O
and O
PAX6 O
is O
clearly O
the O
major O
, O
if O
not O
only O
, O
gene O
responsible O
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

In O
SCA1 B
, O
saccade O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
hypermetria B
. O

In O
SCA1 B
, O
saccade O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
hypermetria B
. O

In O
SCA2 B
, O
saccade O
velocity O
was O
markedly O
decreased O
. O

In O
SCA3 B
, O
gaze B
- I
evoked I
nystagmus I
was O
often O
present O
as O
was O
saccade O
hypometria O
and O
smooth O
pursuit O
gain O
was O
markedly O
decreased O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

In O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demonstrable O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
idiopathic B
ventricular I
fibrillation I
( O
IVF B
) O
. O

A O
distinct O
group O
of O
IVF B
patients O
has O
been O
found O
to O
present O
with O
a O
characteristic O
electrocardiographic O
pattern O
. O

Because O
of O
the O
small O
size O
of O
most O
pedigrees O
and O
the O
high O
incidence O
of O
sudden B
death I
, O
however O
, O
molecular O
genetic O
studies O
of O
IVF B
have O
not O
yet O
been O
done O
. O

Because O
IVF B
causes O
cardiac O
rhythm O
disturbance O
, O
we O
investigated O
whether O
malfunction O
of O
ion O
channels O
could O
cause O
the O
disorder O
by O
studying O
mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
SCN5A O
. O

We O
have O
now O
identified O
a O
missense O
mutation O
, O
a O
splice O
- O
donor O
mutation O
, O
and O
a O
frameshift O
mutation O
in O
the O
coding O
region O
of O
SCN5A O
in O
three O
IVF B
families O
. O

Our O
results O
indicate O
that O
mutations O
in O
cardiac O
ion O
- O
channel O
genes O
contribute O
to O
the O
risk O
of O
developing O
IVF B
. O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

Most O
mutations O
in O
DDS B
patients O
lie O
in O
exon O
8 O
or O
exon O
9 O
, O
encoding O
zinc O
finger O
2 O
or O
zinc O
finger O
3 O
, O
respectively O
, O
with O
a O
hot O
spot O
( O
R394W O
) O
in O
exon O
9 O
. O

We O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B
DMS I
( O
IDMS B
) O
, O
10 O
with O
DDS B
, O
and O
4 O
with O
urogenital B
abnormalities I
and O
/ O
or O
WT B
. O

We O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B
DMS I
( O
IDMS B
) O
, O
10 O
with O
DDS B
, O
and O
4 O
with O
urogenital B
abnormalities I
and O
/ O
or O
WT B
. O

We O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B
DMS I
( O
IDMS B
) O
, O
10 O
with O
DDS B
, O
and O
4 O
with O
urogenital B
abnormalities I
and O
/ O
or O
WT B
. O

We O
report O
WT1 O
heterozygous O
mutations O
in O
16 O
patients O
, O
4 O
of O
whom O
presented O
with O
IDMS B
. O

One O
male O
and O
two O
female O
IDMS B
patients O
with O
WT1 O
mutations O
underwent O
normal O
puberty O
. O

Two O
mutations O
associated O
with O
IDMS B
are O
different O
from O
those O
described O
in O
DDS B
patients O
. O

Two O
mutations O
associated O
with O
IDMS B
are O
different O
from O
those O
described O
in O
DDS B
patients O
. O

No O
WT1 O
mutations O
were O
detected O
in O
the O
six O
other O
IDMS B
patients O
, O
suggesting O
genetic O
heterogeneity O
of O
this O
disease O
. O

This O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
exons O
8 O
and O
9 O
and O
DMS B
; O
( O
2 O
) O
among O
patients O
with O
DMS B
, O
a O
higher O
frequency O
of O
exon O
8 O
mutations O
among O
46 O
, O
XY O
patients O
with O
female O
phenotype O
than O
among O
46 O
, O
XY O
patients O
with O
sexual O
ambiguity O
or O
male O
phenotype O
; O
and O
( O
3 O
) O
statistically O
significant O
evidence O
that O
mutations O
in O
exons O
8 O
and O
9 O
preferentially O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

This O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
exons O
8 O
and O
9 O
and O
DMS B
; O
( O
2 O
) O
among O
patients O
with O
DMS B
, O
a O
higher O
frequency O
of O
exon O
8 O
mutations O
among O
46 O
, O
XY O
patients O
with O
female O
phenotype O
than O
among O
46 O
, O
XY O
patients O
with O
sexual O
ambiguity O
or O
male O
phenotype O
; O
and O
( O
3 O
) O
statistically O
significant O
evidence O
that O
mutations O
in O
exons O
8 O
and O
9 O
preferentially O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

Crystal O
structure O
of O
the O
hemochromatosis B
protein O
HFE O
and O
characterization O
of O
its O
interaction O
with O
transferrin O
receptor O
. O

6 O
A O
crystal O
structure O
of O
HFE O
reveals O
the O
locations O
of O
hemochromatosis B
mutations O
and O
a O
patch O
of O
histidines O
that O
could O
be O
involved O
in O
pH O
- O
dependent O
interactions O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
caused O
by O
a O
CTG O
expansion O
in O
the O
3 O
untranslated O
region O
of O
the O
DM B
gene O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
caused O
by O
a O
CTG O
expansion O
in O
the O
3 O
untranslated O
region O
of O
the O
DM B
gene O
. O

One O
model O
of O
DM B
pathogenesis O
suggests O
that O
RNAs O
from O
the O
expanded O
allele O
create O
a O
gain O
- O
of O
- O
function O
mutation O
by O
the O
inappropriate O
binding O
of O
proteins O
to O
the O
CUG O
repeats O
. O

Splicing O
of O
cTNT O
was O
disrupted O
in O
DM B
striated O
muscle O
and O
in O
normal O
cells O
expressing O
transcripts O
that O
contain O
CUG O
repeats O
. O

Altered O
expression O
of O
genes O
regulated O
posttranscriptionally O
by O
CUG O
- O
BP O
therefore O
may O
contribute O
to O
DM B
pathogenesis O
. O
. O

Familial B
neurohypophyseal I
diabetes I
insipidus I
( O
FNDI B
) O
is O
an O
autosomal B
dominant I
disease I
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
encoded O
by O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
on O
chromosome O
20p13 O
. O

In O
this O
study O
, O
we O
analyzed O
two O
families O
with O
FNDI B
using O
direct O
automated O
fluorescent O
, O
solid O
phase O
, O
single O
- O
stranded O
DNA O
sequencing O
of O
PCR O
- O
amplified O
AVP O
- O
NPII O
DNA O
. O

This O
missense O
mutation O
, O
which O
replaces O
Ala O
with O
Thr O
, O
is O
frequent O
among O
FNDI B
patients O
and O
is O
thought O
to O
reduce O
the O
efficiency O
of O
cleavage O
by O
signal O
peptidases O
. O
. O

Thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
Saethre B
- I
Chotzen I
syndrome I
, O
a O
common O
autosomal B
dominant I
condition I
of O
craniosynostosis B
and O
limb B
anomalies I
, O
were O
screened O
for O
mutations O
in O
TWIST O
, O
FGFR2 O
, O
and O
FGFR3 O
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

Angelman B
syndrome I
( O
AS B
) O
is O
caused O
by O
chromosome O
15q11 O
- O
q13 O
deletions O
of O
maternal O
origin O
, O
by O
paternal O
uniparental B
disomy I
( O
UPD B
) O
15 O
, O
by O
imprinting O
defects O
, O
and O
by O
mutations O
in O
the O
UBE3A O
gene O
. O

Angelman B
syndrome I
( O
AS B
) O
is O
caused O
by O
chromosome O
15q11 O
- O
q13 O
deletions O
of O
maternal O
origin O
, O
by O
paternal O
uniparental B
disomy I
( O
UPD B
) O
15 O
, O
by O
imprinting O
defects O
, O
and O
by O
mutations O
in O
the O
UBE3A O
gene O
. O

Here O
we O
describe O
UBE3A O
coding O
- O
region O
mutations O
detected O
by O
SSCP O
analysis O
in O
13 O
AS B
individuals O
or O
families O
. O

In O
two O
familial O
cases O
and O
one O
sporadic O
case O
, O
mosaicism O
for O
UBE3A O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
AS B
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
AS B
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
AS B
daughter O
. O

In O
two O
familial O
cases O
and O
one O
sporadic O
case O
, O
mosaicism O
for O
UBE3A O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
AS B
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
AS B
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
AS B
daughter O
. O

In O
two O
familial O
cases O
and O
one O
sporadic O
case O
, O
mosaicism O
for O
UBE3A O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
AS B
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
AS B
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
AS B
daughter O
. O

The O
hemochromatosis B
845 O
G O
- O
- O
> O
A O
and O
187 O
C O
- O
- O
> O
G O
mutations O
: O
prevalence O
in O
non O
- O
Caucasian O
populations O
. O

Hemochromatosis B
, O
the O
inherited B
disorder I
of I
iron I
metabolism I
, O
leads O
, O
if O
untreated O
, O
to O
progressive O
iron B
overload I
and O
premature B
death I
. O

The O
hemochromatosis B
gene O
, O
HFE O
, O
recently O
has O
been O
identified O
, O
and O
characterization O
of O
this O
gene O
has O
shown O
that O
it O
contains O
two O
mutations O
that O
result O
in O
amino O
acid O
substitutions O
- O
cDNA O
nucleotides O
845 O
G O
- O
- O
> O
A O
( O
C282Y O
) O
and O
187 O
C O
- O
- O
> O
G O
( O
H63D O
) O
. O

Although O
hemochromatosis B
is O
common O
in O
Caucasians O
, O
affecting O
> O
= O
1 O
/ O
300 O
individuals O
of O
northern O
European O
origin O
, O
it O
has O
not O
been O
recognized O
in O
other O
populations O
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B
suppressor O
APC O
are O
implicated O
in O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
, O
a O
variant O
of O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B
suppressor O
APC O
are O
implicated O
in O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
, O
a O
variant O
of O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B
suppressor O
APC O
are O
implicated O
in O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
, O
a O
variant O
of O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

AAPC B
is O
recognized O
by O
the O
occurrence O
of O
< O
100 O
colonic B
adenomas I
and O
a O
later O
onset O
of O
colorectal B
cancer I
( O
age O
> O
40 O
years O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
genotype O
- O
phenotype O
correlations O
in O
AAPC B
families O
. O

By O
protein O
- O
truncation O
test O
( O
PTT O
) O
assay O
, O
the O
entire O
coding O
region O
of O
the O
APC B
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
AAPC B
kindreds O
, O
and O
their O
phenotypic O
differences O
were O
examined O
. O

By O
protein O
- O
truncation O
test O
( O
PTT O
) O
assay O
, O
the O
entire O
coding O
region O
of O
the O
APC B
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
AAPC B
kindreds O
, O
and O
their O
phenotypic O
differences O
were O
examined O
. O

Five O
novel O
germ O
- O
line O
APC B
mutations O
were O
identified O
in O
seven O
kindreds O
. O

Mutations O
were O
located O
in O
three O
different O
regions O
of O
the O
APC B
gene O
( O
1 O
) O
at O
the O
5 O
end O
spanning O
exons O
4 O
and O
5 O
, O
( O
2 O
) O
within O
exon O
9 O
, O
and O
( O
3 O
) O
at O
the O
3 O
distal O
end O
of O
the O
gene O
. O

In O
individuals O
with O
mutations O
in O
either O
region O
2 O
or O
region O
3 O
, O
the O
average O
number O
of O
adenomas B
tended O
to O
be O
lower O
than O
those O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
although O
age O
at O
diagnosis O
was O
similar O
. O

In O
all O
AAPC B
kindreds O
, O
a O
predominance O
of O
right O
- O
sided O
colorectal B
adenomas I
and O
rectal B
polyp I
sparing O
was O
observed O
. O

Our O
data O
suggest O
that O
, O
in O
AAPC B
families O
, O
the O
location O
of O
the O
APC B
mutation O
may O
partially O
predict O
specific O
phenotypic O
expression O
. O

Our O
data O
suggest O
that O
, O
in O
AAPC B
families O
, O
the O
location O
of O
the O
APC B
mutation O
may O
partially O
predict O
specific O
phenotypic O
expression O
. O

This O
should O
help O
in O
the O
design O
of O
tailored O
clinical O
- O
management O
protocols O
in O
this O
subset O
of O
FAP B
patients O
. O
. O

Deletion O
of O
this O
IC O
abolishes O
local O
paternally O
derived O
gene O
expression O
and O
results O
in O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
have O
created O
two O
deletion O
mutations O
in O
mice O
to O
understand O
PWS B
and O
the O
mechanism O
of O
this O
IC O
. O

Mice O
harbouring O
an O
intragenic O
deletion O
in O
Snrpn O
are O
phenotypically O
normal O
, O
suggesting O
that O
mutations O
of O
SNRPN O
are O
not O
sufficient O
to O
induce O
PWS B
. O

Mice O
with O
a O
larger O
deletion O
involving O
both O
Snrpn O
and O
the O
putative O
PWS O
- O
IC O
lack O
expression O
of O
the O
imprinted O
genes O
Zfp127 O
( O
mouse O
homologue O
of O
ZNF127 O
) O
, O
Ndn O
and O
Ipw O
, O
and O
manifest O
several O
phenotypes O
common O
to O
PWS B
infants O
. O

Mutations O
in O
the O
HEXA O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
A O
( O
Hex O
A O
) O
, O
that O
abolish O
Hex O
A O
enzyme O
activity O
cause O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
, O
the O
fatal O
infantile B
form I
of I
G I
( I
M2 I
) I
gangliosidosis I
, I
Type I
1 I
. O

When O
the O
W474C O
- O
containing O
alpha O
- O
subunit O
was O
transiently O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
Hex O
A O
( O
alphabeta O
) O
in O
COS O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
transfections O
, O
although O
higher O
than O
in O
those O
cells O
transfected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infantile O
TSD B
. O

Pendred B
syndrome I
is O
an O
autosomal B
recessive I
disorder I
characterized O
by O
early O
childhood O
deafness B
and O
goiter B
. O

Pendred B
syndrome I
is O
an O
autosomal B
recessive I
disorder I
characterized O
by O
early O
childhood O
deafness B
and O
goiter B
. O

We O
performed O
mutation O
analysis O
of O
the O
PDS B
gene O
in O
patients O
from O
14 O
Pendred B
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

We O
performed O
mutation O
analysis O
of O
the O
PDS B
gene O
in O
patients O
from O
14 O
Pendred B
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

Pendred B
patients O
in O
three O
non O
- O
consanguineous O
families O
were O
shown O
to O
be O
compound O
heterozygotes O
for O
L236P O
and O
T416P O
. O

The O
identification O
of O
two O
frequent O
PDS B
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
Pendred B
syndrome I
. O

Insertional O
mutation O
by O
transposable O
element O
, O
L1 O
, O
in O
the O
DMD B
gene O
results O
in O
X B
- I
linked I
dilated I
cardiomyopathy I
. O

X B
- I
linked I
dilated I
cardiomyopathy I
( O
XLDCM B
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B
which O
is O
characterized O
by O
preferential O
myocardial B
involvement I
without O
any O
overt O
clinical O
signs O
of O
skeletal B
myopathy I
. O

X B
- I
linked I
dilated I
cardiomyopathy I
( O
XLDCM B
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B
which O
is O
characterized O
by O
preferential O
myocardial B
involvement I
without O
any O
overt O
clinical O
signs O
of O
skeletal B
myopathy I
. O

To O
date O
, O
several O
mutations O
in O
the O
Duchenne B
muscular I
dystrophy I
gene O
, O
DMD O
, O
have O
been O
identified O
in O
patients O
with O
XLDCM B
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
DMD O
with O
the O
XLDCM B
phenotype O
has O
remained O
to O
be O
elucidated O
. O

To O
date O
, O
several O
mutations O
in O
the O
Duchenne B
muscular I
dystrophy I
gene O
, O
DMD O
, O
have O
been O
identified O
in O
patients O
with O
XLDCM B
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
DMD O
with O
the O
XLDCM B
phenotype O
has O
remained O
to O
be O
elucidated O
. O

We O
report O
here O
the O
identification O
of O
a O
unique O
de O
novo O
L1 O
insertion O
in O
the O
muscle O
exon O
1 O
in O
DMD O
in O
three O
XLDCM B
patients O
from O
two O
unrelated O
Japanese O
families O
. O

We O
speculate O
that O
this O
insertion O
of O
an O
L1 O
sequence O
in O
DMD O
is O
responsible O
for O
some O
of O
the O
population O
of O
Japanese O
patients O
with O
XLDCM B
. O
. O

Severe O
early O
- O
onset O
obesity B
, O
adrenal B
insufficiency I
and O
red O
hair O
pigmentation O
caused O
by O
POMC O
mutations O
in O
humans O
. O

Recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
MSH O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
MC4 O
- O
R O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
POMC O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
POMC O
with O
human O
obesity B
. O

Recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
MSH O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
MC4 O
- O
R O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
POMC O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
POMC O
with O
human O
obesity B
. O

The O
dual O
role O
of O
alpha O
- O
MSH O
in O
regulating O
food O
intake O
and O
influencing O
hair O
pigmentation O
predicts O
that O
the O
phenotype O
associated O
with O
a O
defect O
in O
POMC O
function O
would O
include O
obesity B
, O
alteration O
in O
pigmentation O
and O
ACTH B
deficiency I
. O

These O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B
defect I
within O
the O
POMC O
gene O
and O
define O
a O
new O
monogenic B
endocrine I
disorder I
resulting O
in O
early O
- O
onset O
obesity B
, O
adrenal B
insufficiency I
and O
red O
hair O
pigmentation O
. O
. O

Phenylketonuria B
( O
PKU B
) O
and O
mild B
hyperphenylalaninemia I
( O
MHP B
) O
are O
allelic B
disorders I
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

Phenylketonuria B
( O
PKU B
) O
and O
mild B
hyperphenylalaninemia I
( O
MHP B
) O
are O
allelic B
disorders I
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

Phenylketonuria B
( O
PKU B
) O
and O
mild B
hyperphenylalaninemia I
( O
MHP B
) O
are O
allelic B
disorders I
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

In O
the O
present O
study O
, O
the O
classification O
of O
105 O
PAH O
mutations O
may O
allow O
the O
prediction O
of O
the O
biochemical O
phenotype O
in O
> O
10 O
, O
000 O
genotypes O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
hyperphenylalaninemia B
in O
newborns O
. O

A O
( O
CTG O
) O
nexpansion O
in O
the O
3 O
- O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM O
protein O
kinase O
gene O
( O
DMPK O
) O
is O
responsible O
for O
causing O
myotonic B
dystrophy I
( O
DM B
) O
. O

The O
trinucleotide O
repeat O
instability O
mechanisms O
involved O
in O
DM B
and O
other O
human O
genetic B
diseases I
are O
unknown O
. O

We O
studied O
somatic O
instability O
by O
measuring O
the O
CTG O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
transgenic O
mice O
carrying O
a O
( O
CTG O
) O
55expansion O
surrounded O
by O
45 O
kb O
of O
the O
human O
DM B
region O
, O
using O
small O
- O
pool O
PCR O
. O

As O
observed O
in O
some O
of O
the O
tissues O
of O
DM B
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
somatic O
mosaicism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

A O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B
phenotype O
. O

A O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B
phenotype O
. O

We O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
RB1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B
phenotype O
. O

Analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

Maternal B
uniparental I
disomy I
( I
UPD I
) I
for I
chromosome I
15 I
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
report O
on O
an O
unusual O
case O
of O
maternal B
disomy I
15 I
in O
PWS B
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

The O
patient O
( O
J O
. O
B O
. O
) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
PWS B
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

Fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
PWS B
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
PWS B
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
J O
. O

Fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
PWS B
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
PWS B
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
J O
. O

Uniparental B
disomy I
associated O
with O
unbalanced O
segregation O
of O
non O
- O
Robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
PWS B
. O

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
called O
SJS B
type I
2 I
. O

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
called O
SJS B
type I
2 I
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
birth O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
birth O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
birth O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O

To O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
SJS B
type I
2 I
at O
age O
10 O
years O
and O
another O
with O
SWS B
at O
age O
7 O
years O
. O

Patients O
reported O
as O
having O
either O
neonatal O
SJS B
or O
SWS B
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O

Patients O
reported O
as O
having O
either O
neonatal O
SJS B
or O
SWS B
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O

Patients O
reported O
as O
having O
either O
neonatal O
SJS B
or O
SWS B
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O

The O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B
dysplasia I
in O
the O
two O
patients O
( O
one O
with O
SJS B
type I
2 I
, O
one O
with O
SWS B
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

The O
hypothesis O
that O
SWS B
and O
SJS B
type I
2 I
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O
. O

A O
mouse O
model O
of O
severe O
von B
Willebrand I
disease I
: O
defects O
in O
hemostasis O
and O
thrombosis B
. O

Defective O
thrombosis B
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B
injury I
. O

A O
Japanese O
family O
with O
adrenoleukodystrophy B
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

We O
report O
a O
Japanese O
family O
with O
adrenoleukodystrophy B
( O
ALD B
) O
with O
a O
three O
base O
pair O
deletion O
( O
delGAG O
291 O
) O
in O
the O
ALD B
gene O
. O

We O
report O
a O
Japanese O
family O
with O
adrenoleukodystrophy B
( O
ALD B
) O
with O
a O
three O
base O
pair O
deletion O
( O
delGAG O
291 O
) O
in O
the O
ALD B
gene O
. O

We O
report O
a O
Japanese O
family O
with O
adrenoleukodystrophy B
( O
ALD B
) O
with O
a O
three O
base O
pair O
deletion O
( O
delGAG O
291 O
) O
in O
the O
ALD B
gene O
. O

While O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ALD B
type O
. O

The O
tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
Alzheimers B
disease I
( O
AD B
) O
. O

In O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B
of I
the I
cerebral I
white I
matter I
with O
sparing O
of O
the O
U O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ALD B
. O

The O
findings O
in O
this O
family O
suggest O
that O
delGAG291 O
is O
part O
of O
the O
cause O
of O
Japanese O
ALD B
with O
phenotypic O
variations O
. O

Moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
PET O
can O
detect O
an O
insidious B
lesion I
which O
is O
undetectable O
by O
computed O
tomogram O
( O
CT O
) O
or O
MRI O
analysis O
, O
and O
that O
the O
higher O
level O
of O
tau O
reflects O
the O
process O
of O
neuronal B
degeneration I
in O
ALD B
. O

Heterozygous O
mutations O
in O
the O
human O
PAX6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
autosomal B
dominant I
keratitis I
, O
and O
familial B
foveal I
dysplasia I
. O

It O
is O
believed O
that O
the O
mutated O
allele O
of O
PAX6 O
produces O
an O
inactive O
protein O
and O
aniridia B
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

However O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
C O
- O
terminal O
half O
of O
PAX6 O
in O
patients O
with O
Aniridia B
resulting O
in O
mutant O
proteins O
that O
retain O
the O
DNA O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

These O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
PAX6 O
in O
causing O
aniridia B
. O
. O

We O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
VLCAD B
deficiency I
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B
cardiomyopathy I
, O
hepatomegaly B
, O
encephalopathy B
, O
and O
hypotonia B
. O

We O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
VLCAD B
deficiency I
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B
cardiomyopathy I
, O
hepatomegaly B
, O
encephalopathy B
, O
and O
hypotonia B
. O

We O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
VLCAD B
deficiency I
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B
cardiomyopathy I
, O
hepatomegaly B
, O
encephalopathy B
, O
and O
hypotonia B
. O

Clinical O
recognition O
of O
VLCAD B
deficiency I
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B
in O
children O
. O
. O

A O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
DNA O
sequence O
analysis O
within O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
( O
IDDM B
) O
locus O
IDDM4 O
on O
chromosome O
11q13 O
. O

Based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B
. O

The O
APC B
variants O
I1307K O
and O
E1317Q O
are O
associated O
with O
colorectal B
tumors I
, O
but O
not O
always O
with O
a O
family O
history O
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

A O
variant O
of O
FAP B
is O
attenuated B
adenomatous I
polyposis I
coli I
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
APC B
gene O
. O

A O
variant O
of O
FAP B
is O
attenuated B
adenomatous I
polyposis I
coli I
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
APC B
gene O
. O

Attenuated B
adenomatous I
polyposis I
coli I
patients O
have O
" O
multiple O
" O
colorectal B
adenomas I
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
. O

Another O
group O
of O
patients O
with O
multiple O
adenomas B
has O
no O
mutations O
in O
the O
APC B
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

Another O
group O
of O
patients O
with O
multiple O
adenomas B
has O
no O
mutations O
in O
the O
APC B
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

Recently O
, O
however O
, O
a O
missense O
variant O
of O
APC B
( O
I1307K O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B
tumors I
, O
including O
multiple O
adenomas B
, O
in O
Ashkenazim O
. O

Recently O
, O
however O
, O
a O
missense O
variant O
of O
APC B
( O
I1307K O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B
tumors I
, O
including O
multiple O
adenomas B
, O
in O
Ashkenazim O
. O

We O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B
adenomas I
and I
/ I
or I
carcinoma I
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15G O
) O
of O
the O
APC B
gene O
for O
germ O
- O
line O
variants O
. O

There O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
APC B
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B
adenomas I
and I
carcinoma I
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
, O
and O
possibly O
with O
importance O
for O
colorectal B
cancer I
risk O
in O
the O
general O
population O
. O
. O

There O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
APC B
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B
adenomas I
and I
carcinoma I
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
, O
and O
possibly O
with O
importance O
for O
colorectal B
cancer I
risk O
in O
the O
general O
population O
. O
. O

Genomic O
structure O
of O
the O
human O
congenital B
chloride I
diarrhea I
( O
CLD B
) O
gene O
. O

Congenital B
chloride I
diarrhea I
( O
CLD B
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

We O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
CLD B
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

The O
genomic O
structure O
was O
determined O
using O
DNA O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
DNA O
from O
Finnish O
CLD B
patients O
and O
controls O
. O

Genomic O
sequencing O
of O
a O
BAC O
clone O
H O
_ O
RG364P16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
CLD B
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
Pendred B
syndrome I
gene O
( O
PDS B
) O
. O
. O

Genomic O
sequencing O
of O
a O
BAC O
clone O
H O
_ O
RG364P16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
CLD B
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
Pendred B
syndrome I
gene O
( O
PDS B
) O
. O
. O

The O
APCI1307K O
allele O
and O
cancer B
risk O
in O
a O
community O
- O
based O
study O
of O
Ashkenazi O
Jews O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

APC B
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B
. O

APC B
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B
. O

1 O
% O
of O
unselected O
Ashkenazi O
Jews O
and O
higher O
proportions O
of O
Ashkenazim O
with O
family O
or O
personal O
histories O
of O
CRC B
( O
ref O
. O
2 O
) O
. O

To O
evaluate O
the O
role O
of O
I1307K O
in O
cancer B
, O
we O
genotyped O
5 O
, O
081 O
Ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

Sperm O
DNA O
analysis O
in O
a O
Friedreich B
ataxia I
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
FRDA B
gene O
. O

Friedreich B
ataxia I
is O
usually O
caused O
by O
an O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
FRDA B
gene O
. O

Deficiency B
of I
arylsulfatase I
A I
( O
ARSA O
) O
enzyme O
activity O
causes O
metachromatic B
leukodystrophy I
( O
MLD B
) O
. O

A O
number O
of O
ARSA O
gene O
mutations O
responsible O
for O
MLD B
have O
been O
identified O
. O

Recently O
, O
the O
R496H O
mutation O
of O
ARSA O
was O
proposed O
to O
be O
a O
cause O
of O
MLD B
( O
Draghia O
et O
al O
. O
, O
1997 O
) O
. O

To O
discover O
genes O
involved O
in O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B
cell I
carcinoma I
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
VHL O
- O
expressing O
transgenes O
. O

Reintroduced O
wild O
- O
type O
VHL B
strongly O
inhibited O
the O
overexpression O
of O
the O
CA12 O
gene O
in O
the O
parental O
renal B
cell I
carcinoma I
cell O
lines O
. O

Although O
both O
domains O
of O
the O
VHL B
protein O
contribute O
to O
regulation O
of O
CA12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
CA9 O
expression O
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B
. O

Additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
CA O
IX O
and O
CA O
XII O
enzymes O
in O
the O
regulation O
of O
pH O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B
cell O
growth O
. O

Wolfram B
syndrome I
( O
WFS B
; O
OMIM O
222300 O
) O
is O
an O
autosomal B
recessive I
neurodegenerative I
disorder I
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B
- I
dependent I
diabetes I
mellitus I
and O
progressive O
optic B
atrophy I
. O

On O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
WFS B
gene O
was O
localized O
to O
a O
BAC O
/ O
P1 O
contig O
of O
less O
than O
250 O
kb O
. O

Mutations O
in O
a O
novel O
gene O
( O
WFS1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
WFS B
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

Stable O
interaction O
between O
the O
products O
of O
the O
BRCA1 O
and O
BRCA2 O
tumor B
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

A O
novel O
C O
to O
A O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
was O
identified O
by O
sequencing O
amplified O
CYP27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

To O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
French O
Canadian O
cancer B
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

Molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B
impairment I
observed O
in O
most O
DMD B
patients O
. O

Molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B
impairment I
observed O
in O
most O
DMD B
patients O
. O

Complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
DMD B
promoters O
. O

These O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
DMD B
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B
impairment I
associated O
with O
DMD B
. O
. O

These O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
DMD B
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B
impairment I
associated O
with O
DMD B
. O
. O

We O
describe O
a O
French O
Canadian O
hereditary B
non I
- I
polyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hMLH1 O
. O

In O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
I1307K O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B
. O
. O

Hereditary B
coproporphyria I
( O
HCP B
) O
is O
an O
autosomal B
dominant I
disease I
characterized O
by O
a O
deficiency B
of I
coproporphyrinogen I
oxidase I
( O
CPO O
) O
caused O
by O
a O
mutation O
in O
the O
CPO O
gene O
. O

Only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
HCP B
patients O
. O

Five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B
uremic I
syndrome I
( O
HUS B
) O
. O

Factor B
H I
deficiency I
is O
the O
only O
complement B
deficiency I
associated O
with O
HUS B
. O

These O
observations O
suggest O
a O
role O
for O
FH O
and O
/ O
or O
FH O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
HUS B
. O
. O

The O
myotonic B
dystrophy I
( O
DM B
) O
mutation O
is O
an O
unstable O
( O
CTG O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
DM B
chromosomes O
. O

The O
myotonic B
dystrophy I
( O
DM B
) O
mutation O
is O
an O
unstable O
( O
CTG O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
DM B
chromosomes O
. O

Previous O
findings O
in O
Caucasian O
populations O
of O
a O
DM B
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

To O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
DM B
mutation O
exists O
in O
the O
Japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
CTG O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

Six O
different O
haplotypes O
were O
found O
and O
DM B
alleles O
were O
always O
haplotype O
A O
. O

To O
find O
an O
origin O
of O
the O
( O
CTG O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
Japanese O
population O
we O
have O
studied O
90 O
Japanese O
DM B
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

These O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
DM B
and O
Friedreichs B
ataxia I
. O
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
BPAD B
. O

To O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
BPAD B
. O

To O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
BPAD B
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B
disorders I
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B
disorder I
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
Old O
Order O
Amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
BPAD B
. O

To O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
BPAD B
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B
disorders I
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B
disorder I
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
Old O
Order O
Amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
BPAD B
. O

These O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
BPAD B
and O
perhaps O
other O
related O
affective B
disorders I
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disease I
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

This O
results O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
disappearance O
of O
DM B
in O
that O
pedigree O
. O

This O
results O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
disappearance O
of O
DM B
in O
that O
pedigree O
. O

This O
results O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
disappearance O
of O
DM B
in O
that O
pedigree O
. O

The O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
DM B
in O
the O
population O
. O

The O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
DM B
in O
the O
population O
. O

In O
a O
survey O
of O
DM B
in O
Northern O
Ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

Sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
DM B
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

Studies O
on O
meiotic O
drive O
in O
DM B
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
in O
non O
- O
DM O
heterozygotes O
for O
CTGn O
. O

Studies O
on O
meiotic O
drive O
in O
DM B
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
in O
non O
- O
DM O
heterozygotes O
for O
CTGn O
. O

This O
study O
provides O
further O
evidence O
that O
the O
DM B
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

Diagnosis O
of O
hemochromatosis B
. O

If O
untreated O
, O
hemochromatosis B
can O
cause O
serious O
illness O
and O
early B
death I
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

Liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B
, O
which O
can O
affect O
prognosis O
and O
management O
. O

A O
DNA O
- O
based O
test O
for O
the O
HFE O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B
is O
still O
being O
evaluated O
. O

Currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

It O
is O
crucial O
to O
diagnose O
hemochromatosis B
before O
hepatic B
cirrhosis I
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O
. O

Prevalence O
of O
the O
I1307K O
APC B
gene O
variant O
in O
Israeli O
Jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B
cancer I
. O

The O
I1307K O
APC B
gene O
variant O
was O
found O
in O
6 O
. O

METHODS O
DNA O
samples O
from O
500 O
unrelated O
Jews O
of O
European O
or O
non O
- O
European O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B
, O
were O
examined O
for O
the O
I1307K O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
ASO O
) O
method O
. O

4 O
% O
of O
52 O
Ashkenazi O
Israelis O
with O
familial O
cancer B
( O
P O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
European O
Jews O
at O
increased O
cancer B
risk O
. O

4 O
% O
of O
52 O
Ashkenazi O
Israelis O
with O
familial O
cancer B
( O
P O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
European O
Jews O
at O
increased O
cancer B
risk O
. O

Colorectal B
neoplasia I
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
Ashkenazi O
I1307K O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B
. O

Hereditary B
coproporphyria I
( O
HC B
) O
is O
an O
acute O
hepatic B
porphyria I
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B
activity I
of I
coproporphyrinogen I
III I
oxidase I
( O
CPO O
) O
. O

The O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
CPO O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
HC B
patients O
from O
France O
, O
Holland O
, O
and O
Czech O
Republic O
. O

Five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
HC B
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
CPO O
gene B
defects I
reported O
so O
far O
. O
. O

In O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B
leukodystrophy I
( O
MLD B
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
A O
( O
ARSA O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
GS O
) O
excretion O
. O

The O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
ARSA O
and O
GS O
values O
within O
the O
range O
of O
MLD B
patients O
. O

Mutation O
A464V O
was O
not O
found O
in O
18 O
unrelated O
MLD B
patients O
and O
50 O
controls O
. O

A464V O
, O
although O
clearly O
modifying O
ARSA O
and O
GS O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
MLD B
, O
mimicking O
the O
frequent O
ARSA O
pseudodeficiency O
allele O
. O

Our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
MLD B
- O
like O
ARSA O
and O
GS O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

We O
have O
identified O
three O
offspring O
in O
a O
hereditary B
nonpolyposis I
colorectal I
cancer I
family O
who O
developed O
hematological B
malignancy I
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B
type I
1 I
( O
NF1 B
) O
. O

Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B
and O
/ O
or O
lymphoma B
associated O
with O
neurofibromatosis B
type I
1 I
. O
. O

Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B
and O
/ O
or O
lymphoma B
associated O
with O
neurofibromatosis B
type I
1 I
. O
. O

Mutations O
of O
the O
human O
PAX6 O
gene O
underlie O
aniridia B
( O
congenital B
absence I
of I
the I
iris I
) O
, O
a O
rare O
dominant O
malformation B
of I
the I
eye I
. O

The O
spectrum O
of O
PAX6 O
mutations O
in O
aniridia B
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

The O
extraordinary O
conservation O
of O
the O
PAX6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B
patients O
. O

This O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
PAX6 O
mutation O
analysis O
and O
that O
the O
missing O
PAX6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B
. O

Here O
we O
present O
four O
novel O
PAX6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B
pupillae I
( O
displaced B
pupils I
) O
and O
congenital B
nystagmus I
( O
searching B
gaze I
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B
phenotypes O
. O

Emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
. O

These O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B
defects I
in O
EDMD B
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

This O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
A O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
EDMD B
. O

In O
EDMD B
, O
the O
additional O
absence O
of O
lamin O
B1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O
. O

The O
major O
cause O
of O
hepatic B
copper I
accumulation I
in O
man O
is O
a O
dysfunctional O
ATP7B O
gene O
, O
causing O
Wilson B
disease I
( O
WD B
) O
. O

By O
investigating O
the O
common O
autosomal O
recessive O
copper B
toxicosis I
( O
CT B
) O
in O
Bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B
disease I
. O

We O
examined O
whether O
the O
WD B
gene O
ATP7B O
was O
also O
causative O
for O
CT B
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
ATP7B O
and O
C04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

We O
examined O
whether O
the O
WD B
gene O
ATP7B O
was O
also O
causative O
for O
CT B
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
ATP7B O
and O
C04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

C04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
CT B
. O

However O
, O
BAC O
clones O
containing O
ATP7B O
and O
C04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
CFA22q11 O
and O
CFA10q26 O
, O
respectively O
, O
demonstrating O
that O
WD B
cannot O
be O
homologous O
to O
CT B
. O

However O
, O
BAC O
clones O
containing O
ATP7B O
and O
C04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
CFA22q11 O
and O
CFA10q26 O
, O
respectively O
, O
demonstrating O
that O
WD B
cannot O
be O
homologous O
to O
CT B
. O

The O
copper O
transport O
genes O
CTR1 O
and O
CTR2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
CT B
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
CFA11q22 O
. O

Molecular O
analysis O
of O
the O
APC B
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
FAP B
and O
evidence O
for O
the O
role O
of O
APC B
amino O
acid O
changes O
in O
colorectal B
cancer I
predisposition O
. O

Molecular O
analysis O
of O
the O
APC B
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
FAP B
and O
evidence O
for O
the O
role O
of O
APC B
amino O
acid O
changes O
in O
colorectal B
cancer I
predisposition O
. O

Molecular O
analysis O
of O
the O
APC B
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
FAP B
and O
evidence O
for O
the O
role O
of O
APC B
amino O
acid O
changes O
in O
colorectal B
cancer I
predisposition O
. O

BACKGROUND O
/ O
AIMS O
The O
development O
of O
colorectal B
cancer I
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

BACKGROUND O
/ O
AIMS O
The O
development O
of O
colorectal B
cancer I
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

In O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
APC B
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
APC B
mutations O
in O
non O
- O
FAP O
colorectal B
cancer I
. O

In O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
APC B
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
APC B
mutations O
in O
non O
- O
FAP O
colorectal B
cancer I
. O

METHODS O
The O
APC B
gene O
was O
analysed O
in O
190 O
unrelated O
FAP B
and O
15 O
non O
- O
FAP O
colorectal B
cancer I
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

METHODS O
The O
APC B
gene O
was O
analysed O
in O
190 O
unrelated O
FAP B
and O
15 O
non O
- O
FAP O
colorectal B
cancer I
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

RESULTS O
Chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
FAP B
group O
( O
105 O
patients O
) O
. O

Genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
FAP B
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

This O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
APC O
associated O
with O
both O
FAP B
and O
non O
- O
FAP O
colorectal B
cancer I
patients O
. O
. O

Inherited B
colorectal I
polyposis I
and O
cancer B
risk O
of O
the O
APC O
I1307K O
polymorphism O
. O

Germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
APC B
gene O
are O
thought O
to O
initiate O
colorectal B
tumor I
formation O
in O
familial B
adenomatous I
polyposis I
syndrome I
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

Recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
I1307K O
) O
of O
the O
APC B
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
Ashkenazi O
Jewish O
population O
. O

To O
assess O
the O
risk O
of O
this O
common O
APC B
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
Ashkenazi O
Jewish O
subjects O
with O
adenomatous B
polyps I
and O
. O
or O
colorectal B
cancer I
, I
for O
the O
APC O
I1307K O
polymorphism O
. O

Furthermore O
, O
compared O
with O
noncarriers O
, O
APC O
I1307K O
carriers O
had O
increased O
numbers O
of O
adenomas B
and O
colorectal B
cancers I
per O
patient O
( O
P O
= O
. O
03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

We O
conclude O
that O
the O
APC O
I1307K O
variant O
leads O
to O
increased O
adenoma B
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
Ashkenazi O
Jewish O
colorectal B
cancer I
. O

Although O
the O
link O
between O
the O
BRCA1 O
tumour B
- O
suppressor O
gene O
and O
hereditary B
breast I
and I
ovarian I
cancer I
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
BRCA1 O
in O
non B
- I
familial I
cancers I
is O
unclear O
. O

